WEX Pharmaceuticals: Meeting with BGTD of Health Canada
August 25, 2006
Vancouver, BC - (August 24, 2006) - WEX Pharmaceuticals Inc. (the "Company") is pleased to announce that a pre-CTA (Clinical Trial Applications) meeting has been scheduled with the Biologics and Genetic Therapies Directorate (BGTD) of Health Canada on the 5th of September in Ottawa. The purpose of this meeting is to present the results of the new data analysis of the double-blind study (WEX-014) and the long term safety and efficacy study of Tectin(TM) (WEX-014OL) in cancer-related pain. The Company will also discuss the future development of Tectin(TM) with the BGTD.
About WEX Pharmaceuticals Inc.
WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company's Chinese subsidiary sells generic products manufactured at its facility in China.
Forward Looking Statements
This News Release contains forward-looking statements which may not be based on historical fact. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
For additional information on our products, visit us at www.wexpharma.com or call Dr. Edge Wang, President & CEO at 604-683-8880 or 1-800-722-7549.
